Table 2. Summarized clinical and pathological results in tested groups of patients.
| EN (HR+BiH) | NonEN (HR+BiH) | EN-HR | EN-BiH | |
|---|---|---|---|---|
| Creatinin (median, range, umol/l) | 172 (56-1581) | 113 (65-597) | 213 (87-747) | 156 (56-1581) |
| Urea (median, range, mmol/l) | 9.8 (3-51.8) | 8.15 (4.8-28) | 11.8 (3-30.3) | 9.25 (4-51.8) |
| Hemoglobin (mean value, ± standard deviation) | 104.36 ± 24.03 | 119.37 ± 16.54 | 90.76± 24.07 | 110.77 ± 21.51 |
| MDRD mean value, ± standard deviation) | 35.42 ± 25.15 | 51.28 ± 25.52 | 31.64 ± 24.99 | 37.19 ± 25.44 |
| Tumor localization (P-pyelon, U-ureter) | P-28 U-23 P+U-5 |
P-17 U-17 P+U-10 |
P-13 U-6 P+U-1 |
P-15 U-17 P+U-4 |
| Tumor grade (LG/HG) | LG-14 HG-41 |
LG-18 HG-24 |
LG-4 HG-15 |
LG-10 HG-26 |
| Tumor invasion (pTa/pT1 vrs pT2-pT4) | pTa/pT1-15 pT2-pT4-40 |
pTa/pT1-16 pT2-pT4-27 |
pTa/pT1-5 pT2-pT4-14 |
pTa/pT1-10 pT2-pT4-26 |
| Synchronous and/or metachronous tumors | 9/56 (16%) |
12/34 (35.3%) |
3/20 (15%) |
6/36 (16.7) |